# A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

Source: https://onco.cc/trials/nct06725758/  
OnCo record `nct06725758` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ODM-212 in advanced solid tumours, run by Orion Corporation, Orion Pharma, now recruiting.

## Summary

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06725758 by Orion Corporation, Orion Pharma, with 315 participants planned, started 2023-10-26 and due to reach its primary completion in 2027-12-31. Interventions recorded: ODM-212.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06725758
- Phase: 1/2
- Setting: A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
- Sponsor: Orion Corporation, Orion Pharma
- Enrolled: 315

## Sources

- ClinicalTrials.gov NCT06725758: https://clinicaltrials.gov/study/NCT06725758

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06725758.json